Abstract-Venture capital financing is generally considered as the most suitable external financing mode for New technology based SMEs, such as biotech SMEs. However, the way in which venture capital investments influence a firm's innovation performance is not as certain. In this paper, we empirically analyzed the impact of venture capital investments on networks and innovation performance in Korean biotech SMEs. Venture capital investment was positively associated with downstream partnerships, supporting Hypothesis 1-2 (β=0.29, p<0.001) . Inter-firm collaborations were positively correlated with a firm's innovation performance, supporting Hypothesis 2 (β=0.18, p<0.10 in upstream partnerships, β=0.61, p<0.01 in downstream partnerships). This study showed the mechanism of venture capital investment influencing innovation by promoting downstream collaborations.
I. INTRODUCTION
The biotechnology industry is one of the most important industries in a knowledge-based economy, whose development is important for national competitive advantage [1] . The development of the biotechnology sector is based on the emergence of a large number of small-and medium-sized enterprises (SMEs). The novelty and diversity based on the life sciences allowed the emergence of new firms [2] and the development of the biotech sector is based on the entry of a large number of small and medium-sized enterprises (SMEs) [3] . Many researchers focus on fast-growing SMEs as a key mechanism in the sector's development [3] . Biotech SMEs enter into linkages with external entities to acquire resources they lack such as finance resources. Poor access to external financing may limit the growth of biotech SMEs. In developed countries, venture capital financing is generally considered as the most suitable external financing mode for New technology based SMEs [4] . Korean government also has considered venture capital investment as one of the important financing instruments and established several public policies encouraging venture capital. However, there are few empirical studies that investigate the effects of venture capital investment on biotech SMEs in Korea. In this paper, we examine direct and indirect effects of the venture capital investment on innovative performance of biotech SMEs in Korea.
Venture capital investments are defined as equity-linked investments in young, privately held companies, where the investors are financial intermediaries [5] . Previous studies from developed countries have often highlighted the role of the relaxation of financial constraints, coaching, and networking in venture capital investments [4] . Venture capital investments facilitate the funded firm's efforts to obtain other necessary resources. They are particularly skilled at injecting expertise and sound business judgment into investee firms [6] . According to several empirical studies, venture capital investors often perform a key coaching function for the benefit of investee firms [4] , [7] . They provide investee firms, which typically lack internal resources, with advising services in fields such as strategic planning, marketing, finance and budgeting, and human resource management [4] . However, the manner in which venture capital investments influence a firm's innovation performance is not as certain.
In this paper, we empirically analyzed the impact of venture capital investments on networks and innovation performance in Korean biotech SMEs. The main questions that motivated this study were: what is the role of venture capital investments on inter-firm collaboration and innovation performance? What mechanisms of venture capital investment are influencing innovation in developing countries?
The remainder of the paper is structured into three sections. In Section II, we introduce a theoretical framework and research hypotheses, which is followed by data and methods in Section III. Finally, we present main results and discussion.
II. HYPOTHESIS
In this study, we used value-chain based innovation system approach to define a framework. A value-chain based innovation system (VIS) is the combination of a theoretical framework of "systems of innovation" and Porter's concept of a value chain [8] . Porter's concept of a value chain was based on "the process view of organizations, the idea of seeing a manufacturing or service organization as a system," comprising "subsystems each with inputs, transformation processes and outputs"; a product passes through all activities of the chain in order and gains some value at each activity [8] - [10] . In the VIS framework, firms are divided into upstream and downstream companies [1] , [10] .
The biotechnology industry can use VIS analysis because biotech industries are "comprised of a value chain of highly interrelated but distinguishable activities" including R&D, clinical trials, evaluation, manufacturing and sales [1] , [10] .
When considering the main actors in each process, biotech SMEs are located at the hub of a network of upstream and downstream relationships as presented in Table I . Much of the previous studies on inter-firm collaboration implicitly locates biotech SMEs at the upstream pole of the established firms (for example, pharmaceutical or agricultural biotechnology) along industry value chains [10] - [12] . On the other hand, many biotech SMEs collaborate with universities or public research institutions in what are referred to as upstream partnerships [10] , [13] - [16] . Therefore, biotech SMEs serve as "value-added intermediaries" between upstream partners (e.g. universities) and downstream partners (e.g. established enterprises), taking on "a dual role of knowledge transformation and commercialization" [1] , [10] - [16] . Firms receiving venture capital are able to tap into their investors contacts, benefitting from a larger network of potential new customers (e.g. downstream partners), suppliers (e.g. upstream partners), and alliance partners [4] . Furthermore, previous studies showed positive associations between inter-firm collaborations and a firm's innovation performance.
Therefore, we tested a series of hypotheses on the relationship between venture capital investment and a firm's innovation performance, as determined by inter-firm collaborations, which can be classified into upstream partnerships and downstream partnerships.
III. DATA AND METHODS

A. Data
The primary source of the study data was the firm survey conducted in January and February of 2009 [1] . In the survey, we collected the 3-year data from 2005 through 2007 except for information about patent application that was collected from the Korea Intellectual Property Rights Information Service [1] . The sample frame for the survey comprised SMEs (small and medium-sized entrepreneurs) in the biotechnology industry that were listed with the Korea Bio Venture Association, published by the Korea Bio Venture Association, were selected for the survey [1] . The questionnaire comprised three parts: (1) [10] . A total of 152 responses were received which provided a response rate of 46.6 percent [1] . Missing data were handled by listwise deletion-omission of all records that contained a missing data point for any one variable-and this yielded 125 useable responses. Table II shows the general characteristics of the sample: mean age was 8.9 years, mean number of employees per firm was 24.5, and 83.2% of the firms were engaged in R&D. 
B. Definition of Variables
The definitions of the variables used in this study are presented in Table III . The innovation performance of firms was measured by the number of patent applications. We constructed an indicator variable that takes the value one when the firm received venture capital investments and used the total number of formal ties as the measure of inter-firm collaboration, further splitting it into two subcategories: upstream and downstream collaborations. We also controlled the effect of several characteristics of a firm (size, age, position in value chain, internal research and development, etc.). Firm size was controlled by using the log value of the number of employees [10] , [17] . Age was calculated based on the foundation year and month of the firm [10] - [12] , [16] , [18] . Two indexes, POSIT_R and POSIT_D, have been Hypothesis 3: Venture capital financing is positively related to firms' innovation performance. constructed for addressing a firm's position in the value chain, taking the value one when the firm conducted only R&D for POSIT_R and taking the value one when the firm was involved in both R&D and downstream activity for POSIT_D [10] . The ratio of R&D spending to was used as measure of R&D intensity [10] . Stock of patent was calculated as the depreciated sum of applied patents. 
C. Analytical Methods
For estimating the multi-equation model, we used a seemingly unrelated regression (SUR), which was formulated by Zellner [10] , [19] . SUR is a regression in which two or more dependent variables are predicted by sets of predictor variables. In SUR, the estimates are weighted by the covariance of the residuals from the individual regressions which results in SUR producing more efficient estimates than OLS [10] , [20] .
Suppose that the ith equation in a set of m equations is
where y i is an vector of observations on the ith variable, X i is an n×k i matrix of observations on independent variables, i  is a k i ×1 vector of coefficients, and u i is an n×1 vector of disturbances.
The set of equations can be written as 
By definition the variance-covariance matrix for u is
when Substituting (4) 
where I is the identity matrix of size n equal to the number of cases in the analysis and the  is Kronecker multiplication:
each element in is multiplied by I [10] , [21] .
The set of equations are estimated as a group. The GLS estimator is 
The variance-covariance matrix for the GLS estimator is
We analyzed the 3-year panel data using a one way fixed time-effects SUR model.
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IV. RESULTS AND DISCUSSION
Correlations between the variables are presented in Table  IV and results of the SUR analysis are presented in Table V .
Inter-firm collaborations with upstream partners were positively correlated with a firm's innovation performance, supporting Hypothesis 2-1 (β=0.18, p<0.10). Biotech SMEs maintain broad and deep interaction with universities because these interactions increase a firm's stock of knowledge [16] . Zucker et al. investigated co-authorships in the biotechnology industry and argued that new biotechnology firms have a strong dependence on university science research [10] , [15] , [22] , [23] . George et al. found that companies with university linkages had higher levels of innovative output [13] . Baum et al. ' s study showed that biotech start-ups, which had upstream partnerships, generally exhibited stronger performance [24] . The results of our empirical study showed that relationship between venture capital investments and upstream partnerships was positive but statistically insignificant.
We found a strongly significant positive relationships between venture capital investments downstream partnerships, supporting Hypothesis 1-2 (β=0.29, p<0.001) . Downstream activities such as production and marketing are scale intensive activities. While new biotech SMEs specialize in certain types of knowledge, products, and applications, downstream entities such as large established firms have expertise in the commercialization of new inventions that involve large-scale production, marketing and distribution, and regulatory processes [25] . Furthermore, Audretsch found that procuring complementary assets through market exchange is more efficient than acquiring them through internal transactions [26] . Since scale-intensive activities are likely to present more severe obstacles to SMEs, downstream partnerships maybe helpful in overcoming obstacles and entering markets [6] . Because venture capital investors benefit if the investee firm does well and their investment is realized, they maybe more focused on downstream partnerships than upstream partnerships. Downstream partnerships were positively correlated with a firm's innovation performance, supporting Hypothesis 2-2 (β=0.61, p<0.01). When comparing the magnitude of coefficients, it can be found that the effects of downstream partnerships are larger than those of upstream partnerships. Previous studies showed that the complementary nature of collaborations between biotech SMEs and established companies encourages firm performance as well [10] . Rothaermel and Deeds found an inverted U-shaped relationship between the number of alliances and firms' performances [10] , [12] , and Baum et al. showed that biotechnology firms with downstream alliances generally exhibit strong initial performance [10] , [24] .
Results of this study showed no significant direct effect of venture capital investments on innovation performance.
Based on the results of the empirical study, we suggest that venture capital investments influence innovation performance by promoting downstream collaborations.
